Note, Indofarma Sets Ivermectin's Highest Retail Price Of IDR 157,700 For 20 Tablets

Ivermectin 12 mg. (Photo: Antara)

JAKARTA - PT Indofarma Tbk (the Company) as a manufacturer has set the Highest Retail Price (HET) for Ivermectin 12mg drug products at Rp. 157,700 per bottle of 20 tablets. "The Pharmacy Net Price Policy (HNA) includes VAT for Ivermectin tablets 12 mg/bottle of contents. 20 tablets set by the company is Rp123,200 or equivalent to Rp6,160 per tablet. While the Highest Retail Price (HET) including VAT is Rp157,700 or equivalent to Rp7,885 per tablet," wrote Indofarma's official statement received in Jakarta, reported by Antara, Friday, July 2nd. Indofarma obtained a distribution permit granted by BPOM RI with Marketing Permit Number: GKL2120943310A1 for the generic product Ivermectin 12 mg in boxes, 1 bottle @ 20 tablets, on June 20, 2021. The pharmaceutical SOE has a production capacity Ivermectin is currently 4.5 million tablets/month using one line of production facilities. In order to anticipate the needs of the community, the company will increase its capacity to double or more than the current capacity.

With raw materials already available and in the process of being shipped from raw material providers in other countries, the production plan for Ivermectin in early July 2021 to August 2021 is around 13.8 million tablets. Distribution of Ivermectin products is carried out by appointed Pharmaceutical Wholesalers (PBF). "Currently, Ivermectin can be obtained through a doctor's prescription at the Kimia Farma and Halodoc Pharmacy networks, and we will expand the network according to the needs of product distribution to the public. "As part of the Holding BUMN Pharmaceuticals, Indofarma continues to support government programs in the health sector and contribute to improving health status and a better quality of life by committing to provide medicines with guaranteed quality and affordable prices for the community. In addition, the company also helps the government's efforts in pen acceleration handling the COVID-19 pandemic by providing pharmaceutical products and medical devices, as well as health services.